CN103599286A - Traditional Chinese medicine composition for treating fibroid - Google Patents
Traditional Chinese medicine composition for treating fibroid Download PDFInfo
- Publication number
- CN103599286A CN103599286A CN201310557113.7A CN201310557113A CN103599286A CN 103599286 A CN103599286 A CN 103599286A CN 201310557113 A CN201310557113 A CN 201310557113A CN 103599286 A CN103599286 A CN 103599286A
- Authority
- CN
- China
- Prior art keywords
- treatment
- chinese medicine
- medicine composition
- hysteromyoma
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 201000010260 leiomyoma Diseases 0.000 title abstract 3
- 239000004863 Frankincense Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000000454 talc Substances 0.000 claims abstract description 9
- 229910052623 talc Inorganic materials 0.000 claims abstract description 9
- 235000012222 talc Nutrition 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 46
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 35
- 239000002674 ointment Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 12
- 241000717739 Boswellia sacra Species 0.000 claims description 10
- 241001057584 Myrrha Species 0.000 claims description 9
- 241000489492 Arisaema Species 0.000 claims description 7
- 210000000941 bile Anatomy 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 16
- 238000001467 acupuncture Methods 0.000 abstract description 7
- 241000411851 herbal medicine Species 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract 2
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 239000008280 blood Substances 0.000 description 10
- 208000029312 Muscular tumor Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000011837 pasties Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001113 umbilicus Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241001191582 Elasmia cave Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating fibroid, and relates to the technical field of traditional Chinese herbal medicine. The traditional Chinese medicine composition is prepared from the following raw materials by weight: 25g to 35g of unprocessed rhizoma arisaematis, 25g to 35g of frankincense, 25g to 35g of myrrh, 55g to 65g of talcum and 25g to 35g of radix stephaniae tetrandrae. The traditional Chinese medicine composition for treating the fibroid has the characteristics that the raw materials are easy to get, simplicity in preparation can be realized, the cost is low, the practicability is good, and the like, a treating purpose can be realized through the collective effect of the medicine and acupuncture points, characteristics such as simplicity, feasibility and painlessness can be realized, and the traditional Chinese medicine composition can be easily accepted by patients.
Description
Technical field
The present invention relates to field of Chinese herbal medicine technology, be specifically related to a kind of Chinese medicine composition that adopts acupoint plaster treatment hysteromyoma.
Background technology
Hysteromyoma (Uterine Myoma) is the modal benign tumor of female sex organ, is common in 30～50 years old women, and 20 years old following rare.Most hysteromyoma are optimum, but because hysteromyoma tends to multiplely, therefore, in women at reproduction age, with age, muscular tumor may increase and increase gradually, and myomectomy operation is likely recurrence also.(the being sarcomatous change) rate that cancerates of hysteromyoma is very low, is about 0.4-0.8%, but still needs the vigilant risk that cancerates.The risk factor that the generation of hysteromyoma or growth are worked is many-sided.Increase hysteromyoma risk because have: maternal gestational phase application estrogen, age of menarche are little, not fertility, late childbirth, obesity, African American, tamoxifen etc.Reduce hysteromyoma risk because have: exercise, fecund, menopause, oral contraceptive etc.Modern medicine thinks that hysteromyoma is hormone-dependent tumor.Hysteromyoma is apt to occur in the childbearing age, and preadolescence is rare, postmenopausal atrophy or disappearance.Research is thought that estrogen and progestogen is collaborative and is promoted muscular tumor growth.Main mechanism may be follicular phase estrogen raised the Expression of Estrogen and Progesterone Receptors on uterine smooth muscle, progestogen promote that in luteal phase the mitosis of muscular tumor is movable subsequently, thereby have stimulated the growth of muscular tumor.
The traditional Chinese medical science think the morbidity of hysteromyoma and damaged by excess of seven emotions closely related; As menstrual period or puerperal affection of exogenous wind-cold, or internal injury raw food or depressed rage impairing the liver cause in healthy energy damage, internal organs become estranged, and with the passing of time form " leprosy abdominal mass ".In treatment, should to reach, make the fundamentally object of rehabilitation of health in line with the principle for the treatment of must aim at the pathogenesis of disease, rather than take Therapeutic Method blindly.Delay treatment so not only, and can miss best opportunity for the treatment of.
Hysteromyoma is the women of child-bearing age's commonly encountered diseases, and not only sickness rate is high, and is the first cause of hysterectomy.Although operation is these sick effective ways for the treatment of, due to the shortcoming of operation risk, damage and secondary, the trial of exploring non-operative treatment comes into one's own day by day.Modern medicine non-operative treatment hysteromyoma, the main growth that suppresses hysteromyoma by antagonism estrogen activity, even make muscular tumor dwindle, thereby alleviate or alleviate muscular tumor relevant symptoms, but generally can not eliminate and effect a radical cure, often after drug withdrawal, the recovery of sex hormone level in satellite and have the possibility of muscular tumor recurrence or regrowth.And not yet solve long (far) phase or consolidate the problem of curative effect, the safety problem of long-term treatment, the problem such as treatment is machine-processed.
Treatment by Chinese herbs hysteromyoma also has many explorations, Ramulus Cinnamomi Poria pill is the classic prescriptions for the treatment of hysteromyoma, modern Chinese medicine preparation is as GONGLIUQING capsule and some are from intending prescription, all in treatment, trying to explore aspect hysteromyoma, but there is not yet so far by acknowledged, determined curative effect, can eliminate the Chinese medicine preparation of muscular tumor.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of cure rate high, the safe and reliable Chinese medicine composition that is used for the treatment of hysteromyoma.
Technical problem to be solved by this invention realizes by the following technical solutions:
A Chinese medicine composition that is used for the treatment of hysteromyoma, the medicament of being made by the crude drug of following weight, Arisaema Cum Bile 25-35g, Olibanum 25-35g, Myrrha 25-35g, Talcum 55-65g, Radix Stephaniae Tetrandrae 25-35g.
The preferred weight of each crude drug is:
Arisaema Cum Bile 30g, Olibanum 30g, Myrrha 30g, Talcum 60g, Radix Stephaniae Tetrandrae 30g.
The present invention's crude drug used can be bought and obtain from common Chinese shop, and its specification meets national Chinese crude drug standard.
Acupuncture point is selected:
Guan Yuan: ren meridian points.
Location: at hypogastric region, on anterior midline, lower 3 cun when Qizhong.The Mu-front acupoints of small intestinal.
Function: tonifying vital QI, lead red treating stranguria
Qihai:
Location: this acupuncture point is in the hypogastric region of human body, straight line links above umbilicus and pubis, is divided into ten deciles, from the position of umbilicus 3/10, i.e. cave for this reason.
Function: benefiting qi and supporting yang, the solid warp of regulating menstruation
The middle utmost point: bladder the Mu-front acupoints; The meeting of foot three the moon, conception vessel
Location: under umbilicus 4 cun, on ventrimeson, the acupoint selection of lying on the back.
Function: kidney tonifying Xing Yang, leukorrhagia stopping stimulates the menstrual flow
Uterus: extra nerve points, i.e. points not mentioned in the ancient medical classics
Location: at hypogastric region, lower 4 cun when Qizhong, middle extremely side is opened 3 cun.
Function: regulating menstruation is regulated the flow of vital energy, ascending sink.
Usage: above-mentioned prescription drug grinds to form smalls, adds that glycerol is deployed into pasty state, and ointment is placed in and on gauze, makes 6cm*10cm size, the ointment of thickness 2mm, the above-mentioned acupuncture point of external application, once a day 6-8 hour, 3 months courses for the treatment of, treated continuously for 3 courses for the treatment of, finish rear check B ultrasonic the course for the treatment of.
Hysteromyoma belongs to Zhong Yi mass in the abdomen category, primary disease mainly by Chong and Ren channel disorder cold-evil visitor in uterus, coagulation of QI-blood, internal resistance, or hyperactivity of fire caused by deficiency of YIN, or due to stagnation of liver-QI with deficiency of the spleen, Chinese medical discrimination occupies the majority with qi stagnation and blood stasis type, therefore treatment be take Chong and Ren Meridians regulating, vital energy regualting and blood circulation-promoting as main.
Function: promoting blood circulation and breaking stagnation, disease eliminating powder junction
Cure mainly: hysteromyoma (diameter 5cm is following)
Feature: pass unit, Qihai, the middle utmost point of acupoints on Ren channel selected at acupuncture point, adjusts punching to appoint to lead to, and QI and blood regulating, coordinates extra nerve points, i.e. points not mentioned in the ancient medical classics uterus, to dredge, adjusts local QI and blood, reaches blood circulation promoting and blood stasis dispelling, turns the object of hard eliminating stagnation.Choice of drug mass dissipating and swelling eliminating, the poisonous Rhizoma Arisaematis of tonification; With regulating qi and activating blood, analgesic therapy chases after the Olibanum of poison, Myrrha; Inducing diuresis for treating stranguria syndrome, clearing away summer-heat, the Pulvis Talci of damp eliminating sore, inducing diuresis to remove edema, the Radix Stephaniae Tetrandrae of wind-expelling pain-stopping, and modern medicine study finds that Radix Stephaniae Tetrandrae has the immunity of increasing, antitumor action.By medicine and acupuncture point combined effect, reach therapeutic purposes, this law has easy, easy row, painless feature, patient is easy to accept.
Efficiency analysis:
Rhizoma Arisaematis:
[property of medicine] is sweet, flat.GUIXIN, lung, spleen, stomach warp.
[effect] drying dampness to eliminate phlegm, expellings wind and relieving convulsion, mass dissipating and swelling eliminating.
The concentrate formulation of the aqueous extract of [pharmacological action] fresh Rhizoma Arisaematis after alcohol precipitation, test tube test (1:8～1:32 concentration) has inhibitory action to Hela cell, makes cell concentration become agglomerate, destroys normal cell structure, part cell detachment; To mouse experiment tumor, as sarcoma S180, HCA(hepatocarcinoma) solid type, U14(be that squamous epithelial cancer type cervical cancer is transplanted in mice person) etc. also all have an obvious inhibitory action. have report to point out, PEARLITOL 25C has same tumor-inhibiting action, may be one of anticancer effective ingredient.
Olibanum:
[property of medicine] is arduous, temperature.Enter the heart, liver, spleen channel.
[effect] regulating qi and activating blood, analgesic therapy, chases after poison.Control coagulation of QI-blood, trusted subordinate's pain, carbuncle pyogenic infections from tumour or sore, traumatic injury, dysmenorrhea, postnatal blood stasis twinge.
[pharmacological action] this product has more significant analgesic activity. with the uterus ball of taste medicine headed by Olibanum, than the multiple antibacterial stronger bacteriostasis that have, and can effectively kill infusorian.
Myrrha:
[property of medicine] is pungent, bitter, flat.GUIXIN, liver, spleen channel.
[effect] promoting blood circulation and stopping pain, detumescence and promoting granulation.
[pharmacological action] is apt to control all pain of heart stomach flank limbs joint all can control it, and the kind anemofrigid-damp arthralgia of controlling, numb all over the body again, and extremity are unsuccessful and all skin infection are swollen aches.
Talcum:
[property of medicine] is sweet, light, cold.Return bladder, lung, stomach warp.
[effect] inducing diuresis for treating stranguria syndrome, clearing away summer-heat, damp eliminating sore.
The effect Pulvis Talci of [pharmacological action] protection skin and mucosa is because granule is little, and the gross area is large, can a large amount of chemical irritants of sorption or poisonous substance, therefore, when spreading is during in inflammation or damaged organize surperficial, can there is the effect of protection; When for oral administration, except the gastrointestinal mucosa of protection inflammation, bring into play that town is told, anti-diarrhea effect, can also stop the absorption of poisonous substance in gastrointestinal tract.
Radix Stephaniae Tetrandrae:
[property of medicine] gas is cold, the large hardship of taste.Enter bladder, spleen, kidney channel.
[effect] inducing diuresis to remove edema, wind-expelling pain-stopping.
[pharmacological action] edema beriberi, dysuria, eczema sore, rheumatic arthralgia, vascular hypertension.It is generally acknowledged, the effect of Radix Stephaniae Tetrandrae inducing diuresis to remove edema is stronger, and the effect of Radix cocculi laurifolii wind-expelling pain-stopping is better.
Points for attention:
1. diet should be light, gives up alcohol and pungent, raw and cold, greasy food.
2. child, women breast-feeding their children, elderly and infirm should take under doctor instructs.
3. driver, work high above the ground person are cautious use of.
4. strictly pressing usage and dosage uses.
5. pair this medicine and ethanol allergy sufferers are forbidden, and allergic constitution person be cautious use of.
6. when this property of drug changes, ban use of.
7. please this medicine is placed on to the place that child can not contact.
8. as use other medicines, using please Ref Dr or pharmacist before this medicine.
The invention has the beneficial effects as follows: the present invention draws materials easily, makes the features such as simple, with low cost, practicality is good, by medicine and acupuncture point combined effect, reaches therapeutic purposes, this law has easy, easy row, painless feature, patient is easy to accept.
The specific embodiment
For technological means, creation characteristic that the present invention is realized, reach object and effect is easy to understand, below in conjunction with specific embodiment, further set forth the present invention.
Embodiment 1
A Chinese medicine composition that is used for the treatment of hysteromyoma, takes each taste crude drug by following weight: Arisaema Cum Bile 30g, Olibanum 30g, Myrrha 30g, Talcum 60g, Radix Stephaniae Tetrandrae 30g.Said medicine grinds to form smalls, adds that glycerol is deployed into pasty state, and ointment is placed in and on gauze, makes 6cm*10cm size, the ointment of thickness 2mm, unit, Qihai, the middle utmost point, extra nerve points, i.e. points not mentioned in the ancient medical classics, once a day 6-8 hour are being closed in external application, 3 months courses for the treatment of, treated continuously for 3 courses for the treatment of, finish rear check B ultrasonic the course for the treatment of.
Embodiment 2
A Chinese medicine composition that is used for the treatment of hysteromyoma, takes each taste crude drug by following weight: Arisaema Cum Bile 35g, Olibanum 35g, Myrrha 35g, Talcum 65g, Radix Stephaniae Tetrandrae 35g.Said medicine grinds to form smalls, adds that glycerol is deployed into pasty state, and ointment is placed in and on gauze, makes 6cm*10cm size, the ointment of thickness 2mm, unit, Qihai, the middle utmost point, extra nerve points, i.e. points not mentioned in the ancient medical classics, once a day 6-8 hour are being closed in external application, 3 months courses for the treatment of, treated continuously for 3 courses for the treatment of, finish rear check B ultrasonic the course for the treatment of.
Embodiment 3
A Chinese medicine composition that is used for the treatment of hysteromyoma, takes each taste crude drug by following weight: Arisaema Cum Bile 25g, Olibanum 25g, Myrrha 25g, Talcum 55g, Radix Stephaniae Tetrandrae 25g.Said medicine grinds to form smalls, adds that glycerol is deployed into pasty state, and ointment is placed in and on gauze, makes 6cm*10cm size, the ointment of thickness 2mm, unit, Qihai, the middle utmost point, extra nerve points, i.e. points not mentioned in the ancient medical classics, once a day 6-8 hour are being closed in external application, 3 months courses for the treatment of, treated continuously for 3 courses for the treatment of, finish rear check B ultrasonic the course for the treatment of.
Case 1
Have mercy on so-and-so, female, 50 years old, teacher, people from Mingguang City, Anhui Province.Zeng Yin " right ovarian cyst ”Yu Chuzhou City First People's Hospital row operative treatment, recurrence in August then, in San the People's Hospital, Hefei City B ultrasonic, 5.7 * 4.4 * 2.9 centimetres, left ovary, interior a plurality of Nang Qu, 4.8 * 3.4 * 2.5 centimetres, right ovary, Nei Youliangge Nang Qu, 1.8 and 1.7 centimetres, visible 1.6 centimetres of opaques dark area of fluid, rear, uterus, diagnosis many rooms of both ovaries cyst companion pelvic inflammatory disease.Medical in the court after being introduced, give the ointment of the embodiment of the present invention 1 preparation, ointment is placed in and on gauze, makes 6cm*10cm size, the ointment of thickness 2mm, unit, Qihai, the middle utmost point, extra nerve points, i.e. points not mentioned in the ancient medical classics are being closed in external application, 6-8 hour once a day, 3 months courses for the treatment of, treated for 3 courses for the treatment of continuously, finish rear check B ultrasonic the course for the treatment of, 2.7 * 1.7 * 1.5 centimetres, left ovary, 2.3 * 1.6 * 1.5 centimetres, right ovary, bilateral adnexa, uterus are no abnormal, follow up a case by regular visits to not recurrence in a year.
Case 2
Take certain Fuyang City people of ，Nv ，33Sui， Anhui Province.Do not educate after marriage, dysmenorrhea, reaches more than 15 days menstrual period, measures medium, color exhausts, B ultrasonic show left side uterus rear wall have 2 * 2cm hysteromyoma ，Jing institute of traditional Chinese medicine Chinese herbal medicine system oral medication 5 months, hysteromyoma size does not change, and does not think surgical removal, by carrying out here treatment.Give the ointment of the embodiment of the present invention 1 preparation, ointment is placed in and on gauze, makes 6cm*10cm size, the ointment of thickness 2mm, unit, Qihai, the middle utmost point, extra nerve points, i.e. points not mentioned in the ancient medical classics are being closed in external application, 6-8 hour once a day, 3 months courses for the treatment of, treated for 3 courses for the treatment of continuously, finish rear check B ultrasonic the course for the treatment of, hysteromyoma disappears, and the eumenorrhea.Follow up a case by regular visits to not recurrence in a year.
Case 3
People from Jieshou City of Zheng ，Nv ，26Sui， Anhui Province.Dim complexion, dysmenorrhea, the cycle is irregular, reaches menstrual period more than 10 days, measure mediumly, color exhausts, and routine blood test shows that hematochrome is low, and B ultrasonic shows that right side anterior uterine wall has the hysteromyoma of 3 * 4cm, be diagnosed as hysteromyoma, the suggestion excision that operates, but patient will give birth to after considering, disagrees with operative treatment.Medical in the court after being introduced, give the ointment of the embodiment of the present invention 1 preparation, ointment is placed in and on gauze, makes 6cm*10cm size, the ointment of thickness 2mm, unit, Qihai, the middle utmost point, extra nerve points, i.e. points not mentioned in the ancient medical classics, once a day 6-8 hour are being closed in external application, 3 months courses for the treatment of, treated continuously for 3 courses for the treatment of, cure; Follow up a case by regular visits to not recurrence in a year.
More than show and described ultimate principle of the present invention and principal character and advantage of the present invention.The technical staff of the industry should understand; the present invention is not restricted to the described embodiments; that in above-described embodiment and description, describes just illustrates principle of the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements all fall in the claimed scope of the invention.The claimed scope of the present invention is defined by appending claims and equivalent thereof.
Claims (4)
1. a Chinese medicine composition that is used for the treatment of hysteromyoma, is characterized in that: the medicament of being made by the crude drug of following weight,
Arisaema Cum Bile 25-35g, Olibanum 25-35g, Myrrha 25-35g, Talcum 55-65g, Radix Stephaniae Tetrandrae 25-35g.
2. a kind of Chinese medicine composition that is used for the treatment of hysteromyoma according to claim 1, is characterized in that: the medicament of being made by the crude drug of following weight,
Arisaema Cum Bile 30g, Olibanum 30g, Myrrha 30g, Talcum 60g, Radix Stephaniae Tetrandrae 30g.
3. a kind of Chinese medicine composition that is used for the treatment of hysteromyoma according to claim 1 and 2, is characterized in that: described medicament is any suitable preparation clinically.
4. a kind of Chinese medicine composition that is used for the treatment of hysteromyoma according to claim 3, is characterized in that: described preparation is external application medical ointment preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310557113.7A CN103599286A (en) | 2013-11-11 | 2013-11-11 | Traditional Chinese medicine composition for treating fibroid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310557113.7A CN103599286A (en) | 2013-11-11 | 2013-11-11 | Traditional Chinese medicine composition for treating fibroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103599286A true CN103599286A (en) | 2014-02-26 |
Family
ID=50117592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310557113.7A Pending CN103599286A (en) | 2013-11-11 | 2013-11-11 | Traditional Chinese medicine composition for treating fibroid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599286A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547412A (en) * | 2014-12-09 | 2015-04-29 | 李跃 | Traditional Chinese medicine preparation for treating hysteromyoma |
| CN104984281A (en) * | 2015-06-23 | 2015-10-21 | 徐善文 | Chinese herbal ointment for treating hysteromyoma |
| CN105012590A (en) * | 2014-04-15 | 2015-11-04 | 马南行 | Mammary gland hyperplasia preventing and treating pharmaceutical composition |
| CN106237253A (en) * | 2016-09-08 | 2016-12-21 | 四川聚豪生物科技有限公司 | A kind of Chinese medicine composition treating hysteromyoma and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912572A (en) * | 2010-07-30 | 2010-12-15 | 崔宝海 | Multi-effect external plaster |
-
2013
- 2013-11-11 CN CN201310557113.7A patent/CN103599286A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912572A (en) * | 2010-07-30 | 2010-12-15 | 崔宝海 | Multi-effect external plaster |
Non-Patent Citations (1)
| Title |
|---|
| 李艳慧等: "穴位贴敷治疗子宫肌瘤30例疗效观察", 《新中医》, vol. 36, no. 5, 31 May 2004 (2004-05-31) * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012590A (en) * | 2014-04-15 | 2015-11-04 | 马南行 | Mammary gland hyperplasia preventing and treating pharmaceutical composition |
| CN104547412A (en) * | 2014-12-09 | 2015-04-29 | 李跃 | Traditional Chinese medicine preparation for treating hysteromyoma |
| CN104984281A (en) * | 2015-06-23 | 2015-10-21 | 徐善文 | Chinese herbal ointment for treating hysteromyoma |
| CN106237253A (en) * | 2016-09-08 | 2016-12-21 | 四川聚豪生物科技有限公司 | A kind of Chinese medicine composition treating hysteromyoma and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101884770B (en) | Chinese medicinal preparation for treating urolithiasis and preparation method thereof | |
| CN102258658B (en) | Plaster for invigorating blood circulation and relieving pain | |
| CN104189871A (en) | Medicated wine for treating osteoproliferation | |
| CN103585586B (en) | A kind of Chinese medicine composition for the treatment of hysteromyoma and preparation method thereof | |
| CN103800622A (en) | Traditional Chinese medicament for treating prostatitis | |
| CN103599286A (en) | Traditional Chinese medicine composition for treating fibroid | |
| CN102526398A (en) | Externally-used traditional Chinese medicinal preparation for treating chronic pelvic inflammation | |
| CN101569738B (en) | Plaster for treating mastitis, hyperplasia of mammary glands, breast lumps, hydrarthrosis, traumatic injury, preparation method and application thereof | |
| CN101745047A (en) | Chinese medicinal composition for treating gout disease and preparation method thereof | |
| CN103977362A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and early-stage breast cancer | |
| CN104383336B (en) | A kind of Chinese medicine preparation for renal calculus postoperative care and preparation method | |
| CN103908600B (en) | The external used medicine for the treatment of rheumatoid arthritis damp-heat arthralgia resistance card and preparation method | |
| CN102430097A (en) | Traditional Chinese medicine for treating leucoderma | |
| CN102641368B (en) | A kind of Chinese medicine for the treatment of beriberi | |
| CN102824576B (en) | Traditional Chinese medicinal composition for treating psoriasis and preparation method thereof | |
| CN105311137A (en) | External traditional Chinese medicine composition for relieving chronic pelvic pain and dysmenorrheal caused by endometriosis | |
| CN100415288C (en) | A Chinese traditional medicinal preparation for treatment of psoriasis | |
| CN102205067B (en) | Traditional Chinese medicine composition for treating chronic urticaria | |
| CN103585273B (en) | Traditional Chinese medicine composition for treating local swelling and pain | |
| CN1330355C (en) | Chinese medicinal composition for treating ulcer | |
| CN104587401A (en) | Medicine for treating functional constipations | |
| CN104324314A (en) | Pharmaceutical composition for treating gastropathy | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN103041362A (en) | Drug for treating rheumatism and rheumatoid and preparation method thereof | |
| CN102861185A (en) | Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140226 |